Kornimate/medical-research-clean huggingface dataset:
doppler imaging and morbidly adherent placenta

Conditions: Antepartum Hemorrhage

Summary: the aim of this study is to assess the value of adding 3d power doppler (as a diagnostic technique) to gray scale technique in the antenatal diagnosis of morbidly adherent placenta as well as predict the surgical outcome regarding the type of surgery and the intra operative morbidities.


Eligibility criteria:
inclusion criteria: * age: 18 - 45. * pregnant 32 weeks or more. * placenta previa (major and minor). * history of previous cesarean section. exclusion criteria: * medical disorders such as bleeding disorders. * lethal fetal anomalies. * delivery before 34 weeks.
haploidentical allogeneic hematopoietic stem cell transplantation (haplohct) following reduced intensity conditioning (ric) for selected high risk non-malignant diseases

Conditions: Sickle Cell Disease; Thalassemia; High Risk Hematologic Disorders; Cerebral Adrenoleukodystrophy; Inherited Metabolic Disorders

Summary: this is a phase ii study for the use of t-cell replete reduced intensity conditioning (ric) haploidentical donor allogeneic hematopoietic cell transplantation (haplohct) for individuals with high-risk non-malignant diseases who lack a suitable hla-matched sibling donor.


Eligibility criteria:
inclusion criteria: * sickle cell disease (scd) \* if diagnosis of scd must meet one or more of the following disease characteristics: * stroke, cns hemorrhage or a neurologic event lasting longer than 24 hours, or abnormal cerebral mri or cerebral arteriogram or mri angiographic study and impaired neuropsychological testing * acute chest syndrome with a history of recurrent hospitalizations or exchange transfusions * recurrent vaso-occlusive pain 3 or more episodes per year for 3 years or more years or recurrent priapism, * impaired neuropsychological function and abnormal cerebral mri scan * stage i or ii sickle lung disease, * sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate \[gfr\] 30-50% of the predicted normal value) * bilateral proliferative retinopathy and major visual impairment in at least one eye * osteonecrosis of multiple joints with documented destructive changes * requirement for chronic transfusions * rbc alloimmunization * transfusion dependent alpha- or beta-thalassemia * other non-malignant hematologic disorders: transfusion dependent or involve other potential life-threatening cytopenias, including but not limited to paroxysmal nocturnal hemoglobinuria, glanzmann's thrombasthenia, severe congenital neutropenia and shwachman-diamond syndrome * cald * diagnosis of ald by abnormal plasma very long chain fatty acid (vlcfa) profile or abcd1 gene mutation * cerebral disease on mri * absence of a major functional disability (cortical blindness, loss of communication, wheelchair dependence) on the ald neurologic function scale * other inherited metabolic disorders: any other inherited metabolic disorder for which allohct is indicated and for whom, in the opinion of the treating physician, the patient's best treatment option is with a haploidentical donor following non-myeloablatve conditioning. * age, performance status, consent * age: 0-55 years * performance status: karnofsky ≥ 70%, lansky play score ≥ 70 * consent: voluntary written consent (adult or parental/guardian) * adequate organ function * renal: creatinine \ 50 ml/min for children * hepatic: bilirubin and alt \<3 times the upper limit of institutional normal * cardiac: absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction \> 40%. exclusion criteria: * availability of a suitable hla-matched related donor * uncontrolled infection * pregnant or breastfeeding * hiv positive

Keywords: scd cald
clinical and functional outcomes at least 2 years after hamstring muscle repair

Conditions: Hamstring Muscle Repair; Hamstring Rupture

Summary: this study is to evaluate functional outcomes of a new, intraoperative lateral positioning of the anchors on the tuber ischiadicum, in comparison to regular anatomical anchoring direct on top of the tuber ischiadicumafter hamstring muscle repair. this study is to quantify at least 2 years postoperative functional, biomechanical and clinical outcomes including side-to-side differences in muscle strength, unipedal balance, gait, jumping and squatting function, muscle activity, in patients treated by hamstring muscle repair.

the design of this pilot study is a descriptive cross-sectional single centre analysis involving all patients previously treated with hamstring repair. all of these patients will be asked to participate in clinical and detailed functional analysis at least 2 years after surgery. specifically, biomechanical and functional data including isokinetic muscle strength, clinical scores, rom, joint kinematics and kinetics during walking, running, squatting and single leg jumps, muscle activity and single leg balance ability in the affected and contralateral leg will be collected. these parameters will be compared between legs and correlated with clinical scores.

Eligibility criteria:
inclusion criteria: * at least 2 years since hamstring muscle repair exclusion criteria: * revision surgery within 6 months before testing on the ipsilateral knee and hip * bmi \> 35 kg/m2 * previous injury and surgical procedures of the contralateral knee and hip within the last year * neuromuscular disorders affecting lower limb movement * additional pathologies that influence the mobility of the lower extremity * inability to provide informed consent

Keywords: postoperative muscular imbalances muscular deficits pathological gait isokinetic muscle strength
tissue drug levels of hiv medications

Conditions: Human Immunodeficiency Virus

Summary: the aim of this study is to find out why hiv continues to make copies in people taking hiv drugs. the investigators want to know if the medications most people use to treat hiv get into the lymphatic tissue where hiv persists.


Eligibility criteria:
inclusion criteria: * hiv+ * treatment naive or \>30 days off arv therapy * documented sensitivity to prescribed antiretrovirals * age ≥ 18 years * negative pregnancy test for eligible women of childbearing potential * ready to start arv therapy exclusion criteria: * contraindications to surgical \& endoscopy procedures (as judged by pi) * psychiatric or psychological illness that would make adherence to protocol procedures unlikely * pregnancy

Keywords: hiv 1 pharmacokinetics drug levels treatment naive
implementation of team clinic for type 2 diabetes (tct2)

Conditions: Type 2 Diabetes

Summary: the goal of this clinical trial is to learn if shared medical appointment is an acceptable way to deliver care to youth with type 2 diabetes. the main question\[s\] it aims to answer are: * is shared medical appointments an acceptable care delivery model for this population? * does shared medical appointment improve psychosocial outcomes for this population? participants will attend quarterly clinic appointments and group activities and take surveys. researchers will compare this intervention to standard of care.


Eligibility criteria:
patient/aya participants inclusion criteria: * receives care for type 2 diabetes at either chla or ucsf * english speaking youth * youth prescribed medication for type 2 diabetes * english or spanish speaking caregivers * age 12 to 18 years old at the time of enrollment * willingness to attend clinic visits and participate in group session (if randomized to team clinic), complete surveys exclusion criteria: * participants who are non-verbal or unable to participate in group activities and discussions * pregnancy * inability or unwillingness of individual or legal guardian/representative to give written informed assent/consent caregiver/parents participants inclusion criteria: * has a child between the ages of 12 and up to 18 at the time of enrollment who receives care for t2d in the endocrinology clinic at chla. the child must provide consent/assent to participate as a youth participant. * speaks english of spanish. over 95% of our t2d population speaks one of those two languages. our facilitator will be bilingual in english and spanish. it is not feasible for the facilitator to also speak another language. having a language interpreter for discussion groups will affect the dynamics and flow of the group session * willingness to participate in group session (if their child is randomized to team clinic) and complete surveys. exclusion criteria: -inability or unwillingness of individual to give written informed consent
open-label study to assess the long-term safety and efficacy of etelcalcetide (also known as amg 416 or kai-4169) in patients with secondary hyperparathyroidism

Conditions: Secondary Hyperparathyroidism

Summary: the purpose of this study is to evaluate the long term safety and efficacy of thrice weekly intravenous (iv) administration of etelcalcetide in the treatment of secondary hyperparathyroidism (shpt) in patients receiving hemodialysis who had completed 12 weeks of treatment with etelcalcetide in parent study 20120331 (kai-4169-005; nct01414114).


Eligibility criteria:
inclusion criteria: * subject provides written informed consent. * subject completed the 12 week treatment phase in the parent study study 20120331 ( kai-4169-005; nct01414114). exclusion criteria: * subject pregnant or nursing

Keywords: clinical trial, phase 2 renal dialysis secondary hyperparathyroidism chronic kidney disease-mineral and bone disorder parathyroid hormone
a study of aleglitazar in combination with metformin in patients with type 2 diabetes mellitus who are inadequately controlled with metformin alone

Conditions: Diabetes Mellitus Type 2

Summary: this multicenter, randomized, double-blind, placebo-controlled study will assess the efficacy, safety and tolerability of aleglitazar plus metformin combination therapy compared with placebo plus metformin in patients with type 2 diabetes mellitus who are inadequately controlled with metformin monotherapy. patients will be randomized to receive oral doses of 150 mcg aleglitazar once daily or placebo. the anticipated time on study treatment is 26 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=18 years of age * diagnosis of diabetes mellitus type 2 * patients treated with stable metformin monotherapy for at least 12 weeks prior to screening * hba1c \>/=7% and \</=9.5% at screening or within 4 weeks prior to screening and at pre-randomization visit * fasting plasma glucose \</=240 mg/dl at pre-randomization visit * agreement to maintain diet and exercise habits during the study exclusion criteria: * patients with type 1 diabetes mellitus, secondary diabetes, diabetes resulting from pancreatic injury, or acute metabolic diabetic complications within the past 6 months * any previous treatment with thiazolidinedione or a dual ppar agonist * any body weight lowering or lipoprotein-modifying therapy within 12 weeks prior to screening (except stable dose of statin) * symptomatic congestive heart failure classified as new york heart association class ii-iv at screening
safety and efficacy of stem cell therapy in spinal cord injury

Conditions: Spinal Cord Injury

Summary: the aim of this study was to study the effect of stem cell therapy on common symptoms of spinal cord injury patients.

autologous bone marrow mononuclear cells are administered intrathecally by a standard procedure followed by standard rehabilitation therapy.

Eligibility criteria:
inclusion criteria: * diagnosed cases of any type of chronic spinal cord injury * age above 6 months exclusion criteria: * presence of acute infections such as human immunodeficiency virus/ hepatitis b virus/ hepatitis c virus * malignancies * bleeding tendencies * pneumonia * renal failure * severe liver dysfunction * severe anemia \[hemoglobin \< 8\] * any bone marrow disorder * other acute medical conditions such as respiratory infection * pregnancy and lactation

Keywords: spinal cord injury autologous bone marrow mononuclear cells stem cell therapy
symptoms and treatment results in hereditary hemorrhagic telangiectasia

Conditions: Hereditary Haemorrhagic Telangiectasia (HHT)

Summary: hereditary haemorrhagic telangiectasia (hht), also known as rendu-osler-weber syndrome, is an inherited multisystemic disorder with recurrent epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations. the purpose of this study is to provide data about multiple clinical aspects of hht and responses to treatment. for comparison of some aspects also data of non-affected relatives is collected (second cohort). the questionnaire has been designed primarily for web based entry, but can also be circulated in paper format on request.

specific aspects include potential consequences from iron deficiency, efficacy and safety of self-packing, effect of female sex hormones, mortality, effects on the immune system.

Eligibility criteria:
inclusion criteria: * a diagnosis of hereditary haemorrhagic telangiectasia exclusion criteria: * unable to provide informed consent
pivotal study of the capsocam colon (cv-3) in detecting colonic polyps, using colonoscopy as the reference

Conditions: Colonic Polyp

Summary: this study will evaluate the safety and effectiveness of the capsocam colon (cv-3) endoscope system for the detection of colonic polyps.


Eligibility criteria:
inclusion criteria: 1. at least 45-75 years of age 2. committed to undergo a colonoscopy, independent of this study 3. choose to participate and must have signed the irb-approved informed consent document and agreed to release colonoscopy images and results report to sponsor exclusion criteria: 1. colonoscopy or ct-colonography within the past 5 years that demonstrated no polyps 2. has contraindication for capsule endoscopy or colonoscopy 3. subject is suspected or diagnosed with familial adenomatous polyposis, hereditary non polyposis colon cancer, or any high-risk genetic syndrome 4. subject is suspected or diagnosed with inflammatory bowel disease such as ulcerative colitis or crohn's disease 5. history of incomplete colonoscopy 6. type i or uncontrolled ii diabetes (uncontrolled defined as hba1c\>6.4 within the past 3 months and/or with history of constipation or gastroparesis.) 7. impaired cardiac function assessed as greater than nyha class ii 8. history of small- or large-bowel obstructive condition 9. known history of swallowing disorder, and/or ischemic bowel disease neuropathies and/or radiation enteritis 10. known history of nsaid enteropathy and stricture resulting from taking nsaids on a regular basis that, in the opinion of the investigator, would put the subject at greater risk for capsule endoscope retention 11. known allergy to ingredients used in bowel preparation and boosters 12. daily and/or regular narcotic use 13. decompensated cirrhosis 14. prior abdominal radiation therapy 15. diagnosis of anorexia or bulimia 16. history of or suspicion of any of the following: strictures, volvulus or intestinal obstruction, or internal hernias or abdominal surgeries that the investigator believes should exclude the patient from study participation 17. known or suspected megacolon 18. scheduled to undergo mri examination within 7 days after ingestion of the capsule 19. has known slow gastric-emptying time or confirmed diagnosis of gastroparesis 20. pregnant or nursing or is of child-bearing potential and does not practice medically acceptable methods of contraception. wocbp must have a negative urine pregnancy test at screening. 21. unable to follow or tolerate fasting, bowel preparation, and other study procedures 22. any documented medical or psychological condition or significant concurrent illness which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study or would affect the validity of the study results 23. are currently enrolled in an interventional clinical study or currently enrolled in or within the last 30 days, a pharmaceutical clinical study 24. chronic constipation as defined by \<3 bowel movements per week, or the use of routine laxatives (other than fiber) to attain regular bowel movements
comparison of different analgesia drug regimens for pain control during eswl for renal stones

Conditions: Renal Stone

Summary: we want to compare the effect of lignocaine 2 % gel, naproxen sodium and their combination on the pain control during extracorporial shock wave lithotripsy for renal stones.

introduction of eswl (extracorporeal shock wave lithotripsy) has revolutionized the treatment of urolithiasis due to its noninvasive in nature, cost effectiveness, reduced hospitalization time and less morbidity1, 2.impact of shock waves cause pain in most of the patient requiring analgesia or sedation. it is important to make patient pain free to get the maximum possible stone free rates3, 4. opioids are used most commonly for pain relief in eswl but with side effects requiring patient monitoring and delayed hospital stay3, 4. nsaids also showed promising results regarding pain control in eswl without side effects of opoids1, 5. local analgesia gels have controversial role in relieving pain in eswl 1, 6. there are yet no guidelines for pain relief during eswl1, 4. we intend to compare the effect of local analgesia gel, oral nsaids and their combination on pain during lithotripsy.

Eligibility criteria:
inclusion criteria: * age 18 to 70 years having renal stone meet the criteria for eswl exclusion criteria: * h/o chronic use of analgesia, 2) allergy to any of the used medications, 3) those having ureteric stones, 4) serum creatinine\>1.4, 5) pregnant patients, 6) having gastric ulcer disease, 7) not willing to participate, 8) have coagulopathy and 9) active urinary-tract infection.

Keywords: lidocaine gel extracorporeal shockwave lithotripsy naproxen sodium pain score
comparison of ponseti method versus older treatments in talipes equinovarus through gait analysis and clinical results

Conditions: Clubfoot

Summary: there are many different treatments of congenital talipes equinovarus. at our institution, the investigators use the ponseti method with manipulation and immobilization of the foot. in this study the investigators should like to demonstrate the better outcome in clinical results and in gait analysis of patients treated with the ponseti method, compared to the 'older' methods of taping and posteromedial release.

there are many different treatments of congenital talipes equinovarus. at our institution, the investigators use the ponseti method with manipulation and immobilization of the foot. in this study the invistigators should like to demonstrate the better outcome in clinical results and in gait analysis of patients treated with the ponseti method, compared to the 'older' methods of taping and posteromedial release. trial objectives with this study the investigators would like to investigate whether clinical results and gait analysis in patients treated with ponseti has better results compared to patients treated with the older methods.

Eligibility criteria:
inclusion criteria: * all patients with talipes equinovarus who have been treated at our institution exclusion criteria: * patients with other disorders which may influence the clinical or gait analysis outcome
standardized time- and score-oriented treatment of moderate and severe atopic dermatitis

Conditions: Moderate to Severe Atopic Dermatitis

Summary: the study was designed to test the hypothesis whether a standardized, time-and score-oriented treatment following a strict evidence based algorithm is equally effective to a standard treatment regimen for moderate to severe atopic dermatitis. study type: mono-centre study, patients are blinded, physicians are randomized to either treat study- or controll group eligible are patients age 2 years or older with scorad \>= 20 duration: 12 months, study visits every 4 weeks. primary endpoint is difference between baseline scorad and mean scorad under treatment. secundary endpoints are quality of life, safety and economic burden in both treatment groups.


Eligibility criteria:
inclusion criteria: * moderate to severe atopic dermatitis (scorad 20 or more) fulfilling the diagnostic criteria by raika and hanifin exclusion criteria: * pregnancy * nursing * women in childbearing age without contraception * drug - and or alcohol abuse * gene defects that are associated with increased light sensibility, e.g. xeroderma pigmentosum, cockayne syndrome, bloom syndrome

Keywords: atopic dermatitis, atopy
study evaluating ski-606 (bosutinib) in philadelphia chromosome positive leukemias

Conditions: Chronic Myeloid Leukemia

Summary: this is an open-label, continuous daily dosing, two-part safety and efficacy study of ski-606 (bosutinib) in philadelphia chromosome positive leukemias (ph+). part 1 is a dose-escalation study in chronic phase chronic myelogenous leukemia (cml) subjects to establish the maximum tolerated dose (mtd) in this subject population. part 2 has begun after the completion of part 1 and after a dose has been established for the compound in chronic phase subjects. part 2 is a study of the the efficacy of 500mg daily oral ski-606 (bosutinib) in patients with all phases of ph+ cml and ph+ acute lymphocytic leukemia (all). the protocol will test the hypotheses that oral daily dosing of bosutinib at 500 mg will attain (1) major cytogenetic response (mcyr) in chronic phase cml patients and (2) overall hematological response (ohr) in advanced leukemia patients. each phase of the disease will be evaluated as a separate cohort.


Eligibility criteria:
inclusion criteria: * ph+ cml or ph+ all who are primarily refractory to full-dose imatinib (600 mg), have disease progression/relapse while on full-dose imatinib, or are intolerant of any dose of imatinib. * at least 3 months post stem cell transplantation * able to take daily oral capsules/tablets reliably exclusion criteria: * subjects with philadelphia chromosome, and bcr-abl negative cml * overt leptomeningeal leukemia * subjects without evidence of leukemia in bone marrow (extramedullary disease only)

Keywords: leukemia tyrosine kinase inhibitor philadelphia chromosome myeloid philadelphia positive
effect of extracorporeal shock wave on electrophysiological changes and pain in patients with lower cross syndrome

Conditions: Lower Cross Syndrome

Summary: lower cross syndrome happens when there is muscular imbalance between weak and tight muscles. the tight muscles are generally the hip flexors and erector spinae, and weak muscles are the abdominals and gluteal muscles. shortening occurs in the hip flexors while weakening occurs in the abdominals and gluteal muscles.

group i (study): will consist of 22 patients with lower cross syndrome and will receive extracorporeal shock wave in addition to selected physical therapy program. for 12 sessions every other day, each session for 1 hour. group ii (control): will consist of 22 patients with lower cross syndrome and will receive selected physical therapy program only same as group (i). for 12 sessions every other day, each session for 1 hour.

Eligibility criteria:
inclusion criteria: 1. forty-four lower cross syndrome patients from both genders their ages ranged from 30-45 years old. 2. all patients in present study will be ambulant independently. 3. all patients will be medically stable. 4. the body mass index (bmi) will be ranged from 20:25 kg/m2. exclusion criteria: 1. patients with musculoskeletal deformities and disorders. 2. patients with psychiatric disorders or seizures. 3. patients with visual and auditory impairment or tremors influencing balance. 4. patients with other neuromuscular disorders. 5. patients with bmi more than 25 kg/m2. 6. patients with cognitive impairment. 7. patients with lower limb or head and brain surgeries.

Keywords: extracorporeal shock wave electrophysiological changes pain lower cross syndrome